ArticleCancers2021

Risk Stratification, Measurable Residual Disease, and Outcomes of AML Patients with a Trisomy 8 Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.

Donata Backhaus et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.